We are pleased to introduce the founders of Symeres’ daughter company Exemplify: Yadan Chen, CEO, and Paul O’Shea, Chief Scientific Officer. Who are they? What do they stand for? And how does Exemplify fit with Symeres?
Yadan and Paul, could you share something about yourselves that’s not on the website or LinkedIn?
Yadan: As a child, I always had a love for problem-solving games, like riddles and puzzles. My curiosity-driven mentality has made me a student for life. When I’m not in the office, I enjoy competitive tennis and trying out different international cuisine.
Paul: Not surprisingly, as a chemist, I love to cook. I am a big fan of BBQ and recently invested in a smoker. There’s nothing like a nice sunny day in the backyard with a cold beverage (or two), slow cooking a delicious meal to enjoy with friends and family. I am also an avid fan of live music (especially rock music), and in my leisure time, I have attended thousands of events from local bands to stadium shows all over the USA.
What would be the “elevator pitch” for Exemplify if you had to give one?
Exemplify is proud of our “under one roof” offerings in small-molecule CMC development at the pre-IND stage. With combined regulatory–CMC consulting and laboratory expertise located near Princeton, New Jersey, we are optimally suited to serve clients who conduct clinical trials in the USA. Joining the Symeres family allows us to expand our offerings beyond our current capabilities and capacity.
Having made Exemplify such a success, what are you both most proud of so far?
When we founded Exemplify, our focus was to build a differentiated CMC business model in the CRO marketplace that would provide true value to our clients. We are very proud that our unique blend of consulting and laboratory support has enabled many clients to advance their programs through the drug-development process. It is a privilege to be able to contribute to the development of novel medicines that can help improve patients’ lives, and Exemplify is committed to bringing value to our partners and making a positive impact on client’s programs.
What are the special things about the Exemplify culture that you want to maintain as part of the Symeres family?
We are a talent-based organization. Our business success relies on the success and career development of our employees. Our leadership team has made it a priority to build a team focused on collaboration, continuous education, and application of the breadth/depth of their knowledge to the fullest extent possible. We encourage creative thinking, customer focus, and scientific excellence.
How has it been so far? What are your first impressions of interacting with Symeres?
From our first interaction with the Symeres leadership team, we recognized that they, like us, had a true passion for chemistry and scientific excellence. We are all trained chemists, and we speak the same language. Our vision for growth (to become a global leader and full-service CMC powerhouse) is superimposable.
What do you see as the opportunities for the Exemplify–Symeres combination in the coming years?
We are no longer flying solo!
Bringing organizations with a common mission together always creates new opportunities. Exemplify and Symeres have an aligned vision to grow and expand the business and create tangible value for clients. Exemplify will benefit from being part of a larger organization supportive of its growth strategy and will provide the Symeres group with a platform to access new CMC opportunities in the USA. Our expectation is that this will lead to new opportunities for business development, project collaboration, and career development that will enhance business offerings to new and existing clients on both sides of the Atlantic.
Curious what this collaboration can do for your projects? Contact us!
Resources we think you'll love
Blog
When a clean PK profile is actually a warning sign
Blog
CDMO red flags you can’t ignore: Communication breakdowns
Blog
CDMO red flags you can’t ignore: Capacity constraints and resource stretch
Blog
CDMO red flags you can’t ignore: Regulatory shortfalls and misalignment
Whitepaper
5 CDMO red flags you can’t ignore: A guide for biotechs and pharma
Blog
CDMO red flags you can’t ignore: Underestimating technology transfer complexity
Blog
O.N.E Symeres: A practical approach to real-world drug development
Blog
CDMO red flags you can’t ignore: Undefined or shifting project scope
Whitepaper
Accelerating chemical innovation: Unveiling Symeres’ parallel chemistry
Webinar | On-demand
From racemic to pure the art and science of enantiomer separation
Whitepaper
IND & IMPD enabling developability roadmap
Whitepaper
Innovations in unnatural amino acids: Advancing functional diversity and applications
Whitepaper
Leveraging copper-catalyzed ullmann-type cross-coupling reactions in PR&D
Whitepaper
Managing nitrosamines in the pharmaceutical industry: A comprehensive approach
Whitepaper
Optimizing solid-state properties and enhancing API bioavailability through physicochemical prediction
Whitepaper
Stable isotope-labeled compounds
Whitepaper
Unlocking the potential of high-throughput screening: Symegold library design and expansion insights
Interviews
Insights into drug discovery and development 2025
Interviews
Interview with the computer-aided drug design (CADD) department
Interviews
Meet the Organix Director, Mario Gonzalez
Interviews
Interview with the new Managing Director of Symeres Groningen
Interviews
An interview with Anu Mahadevan and Paul Blundell
Blog
Crystalline and liquid crystalline 25-hydroxy-cholest-5-en-3-sulfate sodium and methods for preparing same
Webinar | On-demand
In vivo pharmacokinetic experiments in preclinical drug development
Webinar | On-demand
Accelerating medicinal chemistry by rapid analoging
Webinar | On-demand
Solid-state chemistry part II: Optimal form selection by controlled crystallization
Webinar | On-demand
Route scouting for kilogram-scale manufacturing of APIs
Webinar | On-demand
Solid-state chemistry part I: Introduction
Speak with our experts
Let’s discuss how Symeres can support the discovery and development of your next breakthrough